<DOC>
	<DOCNO>NCT02036216</DOCNO>
	<brief_summary>Circulating free cell DNA ( cfDNA ) extracellular fragmentation nucleic acid occur plasma serum . This kind DNA derive apoptotic/necrotic cell lysis circulate tumor cell ( CTCs ) detectedin patient variety disease . Emerging evidence suggest cfDNA patient exhibit characteristicchanges tumor , suchas mutation , insertions/deletions , methylations , microsatellite aberration , copy number variation , etc . All reveal visible difference benign condition , thus may useful diagnosis cancer , identification target therapy , monitor response treatment , early detection relapse . The purpose study explore characteristic change patient withhepatocellular carcinoma ( HCC ) expect guide target therapy identify non-invasive biomarkers cancer diagnosis prognosis easily isolated circulation .</brief_summary>
	<brief_title>Circulating Cell-free DNA Predictive Biomarker Hepatocelluar Carcinoma .</brief_title>
	<detailed_description>In cancer , cfDNA detect high concentration circulation necrosis neoplasm cell rapid enlargement relatively shortage blood supply . So , identify tumor-specific genetic epigenetic change cfDNA status , gene mutation , deletion , methylation alteration microsatellite alteration , may specific u diagnose neoplasm early phase . This phenomenon also appear patient hepatocellular carcinoma ( HCC ) . Studies show cfDNA level associate intrahepatic extrahepatic metastasis HCC patient examine cfDNAcharacteristic change , p161NK4A , RTL , RASSF1A , LINE-1 GSTP1 . Thus useful u explore specific cfDNA HCC . For high sensitivity specificity detection , use technologiesdeveloped Stanford Genome Technology Centerto find characteristic gene mutation , methylation alteration change ( 3 ) . In study , willinvestigate thesecharacteristic changesin cfDNA primary tumor lesion . Study arrangement : Collect DNA sample plasma , blood cell solid tumor tissue patient HCC . Detect DNA sequence sample plasma , blood cell solid tumor tissue . Identify cancer specific variation cfDNA primary tumor lesion . Date analysis investigate characteristic change . Evaluate application early diagnosis , treatment monitoring prognosis HCC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Age≥18years ≤80 year ; Histologically cytologically proven Hepatocellular carcinoma ChildPugh：child AB Adequate hematological , renal , cardiac pulmonary function Tumor segment liver Uncontrolled systemic disease Reject surgical treatment Metastatic carcinoma ChildPugh：child C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hepatocellular Carcinoma；cell free tumor DNA ; Mutation ;</keyword>
</DOC>